Cited by 326Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychotherapy Techniques and ApplicationsSchizophrenia research and treatment

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

A Randomized Controlled Trial of D-Cycloserine Enhancement of Exposure Therapy for Social Anxiety Disorder

Guastella, Adam J., Richardson, Rick, Lovibond, Peter F., Rapee, Ronald M., Gaston, Jonathan E., Mitchell, Philip, Dadds, Mark R.·2008·Biological Psychiatry

DOI 10.1016/j.biopsych.2007.11.011

Open this paper in CoChat — free account

Abstract

Background Pilot research has suggested that D-cycloserine (DCS) enhances treatment outcomes for anxiety disorders when employed as an adjunct to exposure therapy (ET). The aim of this study was to determine whether 50 mg of DCS enhances ET for social anxiety disorder (SAD) according to a comprehensive set of symptom and life impairment measures.Methods In a randomized double-blind placebo-controlled trial, we administered 50 mg of DCS or placebo in combination with ET to 56 participants who met primary diagnosis for SAD.Results Participants administered DCS reported greater improvement on measures of symptom severity, dysfunctional cognitions, and life-impairment from SAD in comparison with placebo-treated participants. Effect sizes were mostly in the medium range. Results also indicated that the amount of adaptive learning about one's ability to give speeches in front of an audience interacted with DCS to enhance treatment outcome.Conclusions This study shows that the administration of DCS before ET enhances treatment outcomes for SAD. Results also provide the first preliminary evidence to suggest that DCS moderates the relationship between a reduction in negative appraisals about one's speech performance and improvement in overall SAD symptoms.

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2007.11.011

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
Multiple regression: testing and interpreting interactions
(1992) · Choice Reviews Online · doi:10.5860/choice.29-3352 · Cited by 36,647
Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences
Cohen, P., Cohen, P., West, S. G., & Aiken, L. S. (2014) · Psychology Press eBooks · doi:10.4324/9781410606266 · Cited by 20,870
Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences
Kemp, F. (2003) · Journal of the Royal Statistical Society Series D (The Statistician) · doi:10.1046/j.1467-9884.2003.t01-2-00383_4.x · Cited by 9,294
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Social Phobia
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
A brief version of the Fear of Negative Evaluation Scale
Leary, M. R. (1983) · Personality and Social Psychology Bulletin · doi:10.1177/0146167283093007 · Cited by 2,178

Show all 30 references

Sorted by citations

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H., & WFSBP Task Force on Treatment Guide (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 887
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder
Mahan, A. L., & Ressler, K. J. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.06.007 · Cited by 643
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510
How the Neurocircuitry and Genetics of Fear Inhibition May Inform Our Understanding of PTSD
Jovanović, T., & Ressler, K. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09071074 · Cited by 457
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“In summary, the clinical studies performed so far have demonstrated that SSRI augmented psychotherapy holds some benefits for panic disorder patients and possibly for PTSD and SAD patients.”
BackgroundMethodInfluential
A Randomized, Double-Blind Evaluation of d -Cycloserine or Alprazolam Combined With Virtual Reality Exposure Therapy for Posttraumatic Stress Disorder in Iraq and Afghanistan War Veterans
Rothbaum, B. O., Price, M., Jovanovic, T., Norrholm, S. D., Gerardi, M., Dunlop, B., Davis, M., Bradley, B., Duncan, E. J., Rizzo, A., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13121625 · Cited by 388
A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder
Guastella, A. J., Howard, A. L., Dadds, M. R., Mitchell, P., & Carson, D. S. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.01.005 · Cited by 366
Self-citation
The Science of Cognitive Therapy
Hofmann, S. G., Asmundson, G. J. G., & Beck, A. T. (2013) · Behavior Therapy · doi:10.1016/j.beth.2009.01.007 · Cited by 366
Anxiety and Anxiety Disorders
Leigh, H. (2014) · Springer eBooks · doi:10.1007/978-3-319-11005-9_14 · Cited by 309
D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data
Mataix-Cols, D., Fernández de la Cruz, L., Monzani, B., Rosenfield, D., Andersson, E., Pérez-Vigil, A., Frumento, P., de Kleine, R. A., Difede, J., Dunlop, B. W., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.3955 · Cited by 288
Self-citation
Fear extinction and BDNF: translating animal models of PTSD to the clinic
Andero, R., & Ressler, K. J. (2012) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2012.00801.x · Cited by 282
Seeking a Spotless Mind: Extinction, Deconsolidation, and Erasure of Fear Memory
Maren, S. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.023 · Cited by 259
“, 2004) and social anxiety disorder (Guastella et al., 2008), although it did not improve therapeutic outcomes for spider phobics (Guastella et al.”
Background
Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder
Otto, M. W., Tolin, D. F., Simon, N. M., Pearlson, G. D., Basden, S., Meunier, S. A., Hofmann, S. G., Eisenmenger, K., Krystal, J. H., & Pollack, M. H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.036 · Cited by 251
Emerging treatments for PTSD
Cukor, J., Spitalnick, J. S., Difede, J., Rizzo, A., & ROTHBAUM, B. O. (2009) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.09.001 · Cited by 251
A Randomized Placebo-Controlled Trial of d-Cycloserine to Enhance Exposure Therapy for Posttraumatic Stress Disorder
de Kleine, R. A., Hendriks, G.-J., Kusters, W. J. C., Broekman, T. G., & van Minnen, A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.033 · Cited by 220
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain
Harvey, R. J., & Yee, B. K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3893 · Cited by 213
D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial
Difede, J., Cukor, J., Wyka, K., Olden, M., Hoffman, H., Lee, F. S., & Altemus, M. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.317 · Cited by 212
New perspectives in glutamate and anxiety
Riaza Bermudo-Soriano, C., Perez-Rodriguez, M. M., Vaquero-Lorenzo, C., & Baca-Garcia, E. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.010 · Cited by 207
A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder
Blanco, C., Heimberg, R. G., Schneier, F. R., Fresco, D. M., Chen, H., Turk, C. L., Vermes, D., Erwin, B. A., Schmidt, A. B., Juster, H. R., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.11 · Cited by 206
Impaired Extinction Retention in Adolescent Rats: Effects of D-Cycloserine
McCallum, J., Kim, J. H., & Richardson, R. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.92 · Cited by 198
Self-citation
A randomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorder
Litz, B. T., Salters-Pedneault, K., Steenkamp, M. M., Hermos, J. A., Bryant, R. A., Otto, M. W., & Hofmann, S. G. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.05.006 · Cited by 196
A Preliminary Study of D-Cycloserine Augmentation of Cognitive-Behavioral Therapy in Pediatric Obsessive-Compulsive Disorder
Storch, E. A., Murphy, T. K., Goodman, W. K., Geffken, G. R., Lewin, A. B., Henin, A., Micco, J. A., Sprich, S. E., Wilhelm, S., Bengtson, M. A., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.015 · Cited by 193
Pharmacological treatment of anxiety disorders: Current treatments and future directions
Farach, F. J., Pruitt, L. D., Jun, J. J., Jerud, A. B., Zoellner, L. A., & Roy‐Byrne, P. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2012.07.009 · Cited by 202
Pharmacological treatment of PTSD – Established and new approaches
Steckler, T., & Risbrough, V. B. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.012 · Cited by 188
Glutamate Receptors in Extinction and Extinction-Based Therapies for Psychiatric Illness
Myers, K. M., Carlezon, W. A., & Davis, M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.88 · Cited by 177
Cannabinoid facilitation of fear extinction memory recall in humans
Rabinak, C. A., Angstadt, M., Sripada, C. S., Abelson, J. L., Liberzon, I., Milad, M. R., & Phan, K. L. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.063 · Cited by 163
Cannabinoid modulation of prefrontal–limbic activation during fear extinction learning and recall in humans
Rabinak, C. A., Angstadt, M., Lyons, M., Mori, S., Milad, M. R., Liberzon, I., & Phan, K. L. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.09.009 · Cited by 148
Analysis of free d-serine in mammals and its biological relevance
Nishikawa, T. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.08.030 · Cited by 145
D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia
Smits, J. A. J., Rosenfield, D., Otto, M. W., Powers, M. B., Hofmann, S. G., Telch, M. J., Pollack, M. H., & Tart, C. D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.12.009 · Cited by 142
Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression
MacDonald, K., MacDonald, T. M., Brüne, M., Lamb, K., Wilson, M. P., Golshan, S., & Feifel, D. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.05.014 · Cited by 140
Neurobiological correlates of cognitions in fear and anxiety: A cognitive-neurobiological information processing model
Hofmann, S. G., Ellard, K. K., & Siegle, G. J. (2012) · Cognition and Emotion · doi:10.1080/02699931.2011.579414 · Cited by 132
Social fearfulness in the human brain
Miskovic, V., & Schmidt, L. A. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.08.002 · Cited by 126
d-Cycloserine as an Augmentation Strategy With Cognitive-Behavioral Therapy for Social Anxiety Disorder
Hofmann, S. G., Smits, J. A. J., Rosenfield, D., Simon, N., Otto, M. W., Meuret, A. E., Marques, L., Fang, A., Tart, C., & Pollack, M. H. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12070974 · Cited by 121
Deletion of Glutamate Delta-1 Receptor in Mouse Leads to Aberrant Emotional and Social Behaviors
Yadav, R., Gupta, S. C., Hillman, B. G., Bhatt, J. M., Stairs, D. J., & Dravid, S. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032969 · Cited by 129
D-serine as a gliotransmitter and its roles in brain development and disease
Horn, M. R. V., Sild, M., & Ruthazer, E. S. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00039 · Cited by 126
Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: A randomized placebo controlled trial of yohimbine augmentation
Powers, M. B., Smits, J. A. J., Otto, M. W., Sanders, C., & Emmelkamp, P. M. G. (2009) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2009.01.001 · Cited by 122
Evidence-Based Psychological Treatments: An Update and a Way Forward
Barlow, D. H., Bullis, J. R., Comer, J. S., & Ametaj, A. A. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185629 · Cited by 120
D-cycloserine facilitates context-specific fear extinction learning
Bouton, M. E., Vurbic, D., & Woods, A. M. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.07.003 · Cited by 118
“In humans, DCS administration can likewise facilitate the loss of fear resulting from exposure that causes incomplete fear loss in controls (acrophobia: Ressler et al., 2004; social phobia: Guastella et al., 2008; Hofmann et al., 2006; obsessive–compulsive disorder: Kushner et al., 2007).”
Background
NMDA receptors and fear extinction: implications for cognitive behavioral therapy
Davis, M. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/mdavis · Cited by 120
The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia
Labrie, V., & Roder, J. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.08.002 · Cited by 118
D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions
Smits, J. A. J., Rosenfield, D., Otto, M. W., Marques, L., Davis, M. L., Meuret, A. E., Simon, N. M., Pollack, M. H., & Hofmann, S. G. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.06.020 · Cited by 114
“…(DCS) for enhancing exposure therapy has been variable across these studies, with several evidencing strong augmentative effects of DCS (Guastella et al., 2008; Hofmann et al., 2006; Otto et al., 2010; Ressler et al., 2004), and several showing either relatively weak effects (Kushner…”
Background
The gut microbiome in social anxiety disorder: evidence of altered composition and function
Butler, M., Bastiaanssen, T. F. S., Long-Smith, C. M., Mörkl, S., Berding, K., Ritz, N. L., Strain, C., Patangia, D. V., Patel, S. H., Stanton, C., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02325-5 · Cited by 120
Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis
Rodrigues, H., Figueira, I., Lopes, A., Gonçalves, R., Mendlowicz, M. V., Coutinho, E. S. F., & Ventura, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093519 · Cited by 109
The use of cognitive enhancers in animal models of fear extinction
Kaplan, G. B., & Moore, K. A. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.01.009 · Cited by 113
How to erase memory traces of pain and fear
Sandkühler, J., & Lee, J. L. C. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.03.004 · Cited by 108
Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d -Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder
Storch, E. A., Wilhelm, S., Sprich, S. E., Henin, A., Micco, J. A., Small, B. J., Mcguire, J. F., Mutch, P. J., Lewin, A. B., Murphy, T. K., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.1128 · Cited by 111
Structural Determinants of d-Cycloserine Efficacy at the NR1/NR2C NMDA Receptors
Dravid, S. M., Burger, P. B., Prakash, A., Geballe, M. T., Yadav, R., Le, P., Vellano, K. M., Snyder, J. P., & Traynelis, S. F. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.5390-09.2010 · Cited by 108
Translating Across Circuits and Genetics Toward Progress in Fear- and Anxiety-Related Disorders
Ressler, K. J. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20010055 · Cited by 104
BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity
Rakofsky, J. J., Ressler, K. J., & Dunlop, B. W. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.121 · Cited by 112
Empirically Supported Treatments for Panic Disorder
McHugh, R. K., Smits, J. A. J., & Otto, M. W. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.005 · Cited by 106
Evidence‐based treatments for PTSD, new directions, and special challenges
Cukor, J., Olden, M., Lee, F. L. F., & Difede, J. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05793.x · Cited by 105
Posttraumatic Stress Disorder
Schmertz, S. K., & Gerardi, M. A. (2013) · Wiley eBooks · doi:10.1002/9781118528563.wbcbt43 · Cited by 102
The evidence-based pharmacotherapy of social anxiety disorder
Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000119 · Cited by 99
The N-Methyl-D-Aspartate Receptor Co-agonist D-Cycloserine Facilitates Declarative Learning and Hippocampal Activity in Humans
Onur, O. A., Schlaepfer, T. E., Kukolja, J., Bauer, A., Jeung, H., Patin, A., Otte, D.-M., Shah, N. J., Maier, W., Kendrick, K. M., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.022 · Cited by 97
Social Anxiety Disorder
Wong, J., Gordon, E. A., & Heimberg, R. G. (2012) · Handbook of Evidence-Based Practice in Clinical Psychology · doi:10.1002/9781118156391.ebcp002027 · Cited by 96
DIFFICULT-TO-TREAT PEDIATRIC OBSESSIVE-COMPULSIVE DISORDER: FEASIBILITY AND PRELIMINARY RESULTS OF A RANDOMIZED PILOT TRIAL OF d -CYCLOSERINE-AUGMENTED BEHAVIOR THERAPY
Farrell, L. J., Waters, A. M., Boschen, M. J., Hattingh, L., McConnell, H. W., Oar, E. L., Collings, N., Zimmer‐Gembeck, M. J., Shelton, D., Ollendick, T. H., et al. (2013) · Depression and Anxiety · doi:10.1002/da.22132 · Cited by 98
Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders
Ori, R., Amos, T., Bergman, H., Soares‐Weiser, K., Ipser, J., & Stein, D. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007803.pub2 · Cited by 104
Treatment of addiction and anxiety using extinction approaches: Neural mechanisms and their treatment implications
Kaplan, G. B., Heinrichs, S. C., & Carey, R. J. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.08.004 · Cited by 92
d-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial
Siegmund, A., Golfels, F., Finck, C., Halisch, A., Räth, D., Plag, J., & Ströhle, A. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.01.020 · Cited by 89
Mental health impact of the Iraq and Afghanistan conflicts: A review of US research, service provision, and programmatic responses
Wells, T. S., Miller, S. C., Adler, A. B., Engel, C. C., Smith, T. C., & Fairbank, J. A. (2011) · International Review of Psychiatry · doi:10.3109/09540261.2011.558833 · Cited by 93
Ultrasonic vocalizations as a fundamental tool for early and adult behavioral phenotyping of Autism Spectrum Disorder rodent models
Caruso, A., Ricceri, L., & Scattoni, M. L. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.06.011 · Cited by 87
Chronic Antidepressant Treatment Impairs the Acquisition of Fear Extinction
Burghardt, N. S., Sigurdsson, T., Gorman, J. M., McEwen, B. S., & LeDoux, J. E. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.012 · Cited by 94
Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: medication effects, glucocorticoids, and attenuated treatment outcomes.
Otto, M. W., McHugh, R. K., & Kantak, K. M. (2010) · Clinical Psychology Science and Practice · doi:10.1111/j.1468-2850.2010.01198.x · Cited by 87
Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: Focus on pharmacology and preclinical translational models
Harvey, B. H., & Shahid, M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.014 · Cited by 90
Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology
Nasir, M., Trujillo, D., Levine, J. L. S., Dwyer, J. B., Rupp, Z. W., & Bloch, M. H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.548505 · Cited by 94
Yohimbine Enhancement of Exposure Therapy for Social Anxiety Disorder: A Randomized Controlled Trial
Smits, J. A. J., Rosenfield, D., Davis, M. L., Julian, K., Handelsman, P. R., Otto, M. W., Tuerk, P., Shiekh, M., Rosenfield, B., Hofmann, S. G., et al. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.008 · Cited by 86
D-Cycloserine Facilitation of Fear Extinction and Exposure-Based Therapy Might Rely on Lower-Level, Automatic Mechanisms
Grillon, C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.017 · Cited by 80
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.
Krystal, J. H., Tolin, D. F., Sanacora, G., Castner, S. A., Williams, G. V., Aikins, D. E., Hoffman, R. E., & D'Souza, D. C. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.002 · Cited by 76
d-Cycloserine Augmentation of Cognitive Behavioral Therapy for Anxiety Disorders: an Update
Hofmann, S. G., Otto, M. W., Pollack, M. H., & Smits, J. A. J. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0532-2 · Cited by 76
Effects of Post-Session Administration of Methylene Blue on Fear Extinction and Contextual Memory in Adults With Claustrophobia
Telch, M. J., Bruchey, A. K., Rosenfield, D., Cobb, A. R., Smits, J. A. J., Pahl, S. A., & Gonzalez-Lima, F. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101407 · Cited by 77
Testing the effects of Δ9-THC and D-cycloserine on extinction of conditioned fear in humans
Klumpers, F., Denys, D., Kenemans, J. L., Grillon, C., van der Aart, J., & Baas, J. M. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431624 · Cited by 72
D-Cycloserine Effects on Extinction of Conditioned Responses to Drug-Related Cues
Myers, K. M., & Carlezon, W. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.030 · Cited by 72
Pharmacological Discrimination of Extinction and Reconsolidation of Contextual Fear Memory by a Potentiator of AMPA Receptors
Yamada, D., Zushida, K., Wada, K., & Sekiguchi, M. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.86 · Cited by 72
Immediate extinction causes a less durable loss of performance than delayed extinction following either fear or appetitive conditioning
Woods, A. M., & Bouton, M. E. (2008) · Learning & Memory · doi:10.1101/lm.1078508 · Cited by 70
Enhancement of psychosocial treatment with D-cycloserine: Models, moderators, and future directions
Otto, M. W., Kredlow, M. A., Smits, J. A. J., Hofmann, S. G., Tolin, D. F., de Kleine, R. A., van Minnen, A., Evins, A. E., & Pollack, M. H. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.09.007 · Cited by 70
Evidence-Based Treatment of Post-Traumatic Stress Disorder
Difede, J., Olden, M., & Cukor, J. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-051812-145438 · Cited by 70
d-Cycloserine Augmentation of Behavioral Therapy for the Treatment of Anxiety Disorders: A Meta-Analysis
Bontempo, A., Panza, K. E., & Bloch, M. H. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11r07356 · Cited by 69
Aggression in young children with concurrent callous–unemotional traits: can the neurosciences inform progress and innovation in treatment approaches?
Dadds, M. R., & Rhodes, T. (2008) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2008.0029 · Cited by 69
Self-citation
SLEEP QUALITY PREDICTS TREATMENT OUTCOME IN CBT FOR SOCIAL ANXIETY DISORDER: Sleep Quality and CBT for Social Anxiety
Zalta, A. K., Dowd, S., Rosenfield, D., Smits, J. A. J., Otto, M. W., Simon, N. M., Meuret, A. E., Marques, L., Hofmann, S. G., & Pollack, M. H. (2013) · Depression and Anxiety · doi:10.1002/da.22170 · Cited by 68
Cognitive enhancers for anxiety disorders
Hofmann, S. G., Smits, J. A. J., Asnaani, A., Gutner, C. A., & Otto, M. W. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.11.020 · Cited by 69
Does Yohimbine Hydrochloride Facilitate Fear Extinction in Virtual Reality Treatment of Fear of Flying? A Randomized Placebo-Controlled Trial
Meyerbröker, K., Powers, M. B., van Stegeren, A. H., & Emmelkamp, P. M. G. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000329454 · Cited by 69
Augmentation of Cognitive Behavioral Therapy with Pharmacotherapy
Ganasen, K. A., Ipser, J., & Stein, D. J. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.04.008 · Cited by 68
A window of vulnerability: Impaired fear extinction in adolescence
Baker, K., Den, M. L., Graham, B. M., & Richardson, R. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.10.009 · Cited by 73
Self-citation
Critical Parameters for d -Cycloserine Enhancement of Cognitive-Behaviorial Therapy for Obsessive-Compulsive Disorder
ROTHBAUM, B. O. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07121871 · Cited by 66
Current status of knowledge on public-speaking anxiety
Pull, C. B. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32834e06dc · Cited by 66
Paroxetine, Cognitive Therapy or Their Combination in the Treatment of Social Anxiety Disorder with and without Avoidant Personality Disorder: A Randomized Clinical Trial
Nordahl, H., Vogel, P. A., Morken, G., Stiles, T., Sandvik, P., & Wells, A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447013 · Cited by 60
Treatment of avoidance behavior as an adjunct to exposure therapy: Insights from modern learning theory
Treanor, M., & Barry, T. J. (2017) · Behaviour Research and Therapy · doi:10.1016/j.brat.2017.04.009 · Cited by 65
D-Cycloserine Facilitates Extinction the First Time but not the Second Time: An Examination of the Role of NMDA Across the Course of Repeated Extinction Sessions
Langton, J. M., & Richardson, R. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.32 · Cited by 63
Self-citation
Learning Principles in CBT
Davis, M. L., Witcraft, S. M., Baird, S. O., & Smits, J. A. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803457-6.00003-9 · Cited by 73
Pharmacotherapy for anxiety disorders in children and adolescents
Kodish, I., Rockhill, C., & Varley, C. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/ikodish · Cited by 62
d-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders
Hofmann, S. G., Wu, J. Q., & Boettcher, H. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-11 · Cited by 59
Cognitive enhancers for facilitating drug cue extinction: Insights from animal models
Dhonnchadha, B. Á. N., & Kantak, K. M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.01.018 · Cited by 57
Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder
McGuire, J. F., Lewin, A. B., & Storch, E. A. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.934677 · Cited by 57
“When conducting a session-by-session analysis, Smits et al. [75] found a significant relationship between end of session fear (i.e., within-session fear habituation) and the LSAS rating at the following session for participants receiving YHCL, but not placebo.”
BackgroundInfluential
Therapeutic strategies for social anxiety disorder: where are we now?
Pélissolo, A., Kassm, S. A., & Delhay, L. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1666713 · Cited by 60
Neuropharmacological Modulation of N-methyl-D-aspartate, Noradrenaline and Endocannabinoid Receptors in Fear Extinction Learning: Synaptic Transmission and Plasticity
Battaglia, S., Fazio, C. D., Vicario, C. M., & Avenanti, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065926 · Cited by 56
Pharmacological enhancement of fear reduction: preclinical models
Graham, B. M., Langton, J. M., & Richardson, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01175.x · Cited by 57
Self-citation

Authors: Guastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., & Dadds, M. R.
Affiliations: UNSW Sydney (AU)
Macquarie University (AU)
Corresponding author: Guastella, Adam J.
ORCID: Guastella, Adam J.
Richardson, Rick
Lovibond, Peter F.
Rapee, Ronald M.
Gaston, Jonathan E.
Mitchell, Philip
Dadds, Mark R.
Venue: Biological Psychiatry
Publisher: Elsevier BV
Published: 2008-03
Volume: 63
Issue: 6
Pages: 544-549
ISSN: 0006-3223 (ISSN-L)
DOI: 10.1016/j.biopsych.2007.11.011
OpenAlex: W2028445187
Semantic Scholar: e41984c470918166ac39c6aec20bd21dfc842860
Cited by: 326
References: 30
Citations by year: 2026: 1 · 2025: 3 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 9 · 2020: 5 · 2019: 9 · 2018: 13 · 2017: 23 · 2016: 12 · 2015: 15 · 2014: 41 · 2013: 32 · 2012: 31
FWCI: 53.98
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Biological Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Health and Medical Research Council (350963)
Topics: Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords: D-cycloserine, social anxiety disorder, exposure therapy, adjunctive pharmacotherapy, treatment enhancement, speech performance, dysfunctional cognitions, negative appraisals
MeSH terms: Adolescent, Adult, Combined Modality Therapy, Cycloserine, Desensitization, Psychologic, Double-Blind Method, Fear, Female, Humans, Male, Middle Aged, New South Wales, Phobic Disorders, Premedication, Speech

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Randomized Controlled Trial of D-Cycloserine Enhancement of Exposure Therapy for Social Anxiety Disorder

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks